Myeloma
The latest news, research, and perspectives in multiple myeloma. Myeloma is a hematologic malignancy characterized by the proliferation of malignant plasma cells that produce monoclonal immunoglobulin. These neoplastic cells result in characteristic clinical features that include bone lytic lesions, hypercalcemia, renal insufficiency, and anemia.
Novel therapies and “game-changing drugs” have made a major impact on the treatment of myeloma, Dr. Wong said.
Patients with clinical progression had a significantly shorter median OS from their first relapse.
Sandy Wong, MD, explains how clinicians and researchers can help educate others about myeloma.
Molly Stoddart, RN, BSN, is a clinical research nurse on the multiple myeloma team at the Winship Cancer Institute at Emory.
Around two-thirds of second primary malignancies were solid malignancies and 20% were myeloid malignancies.
Sandy Wong, MD, explains what Myeloma Awareness Month means to her as a clinician and a researcher.
The “greatest benefit" was observed in those who had t(4;14) or amp1q21.
Frailty measures have been "increasingly incorporated" in multiple myeloma trials in recent years.
Sagar Lonial, MD, FACP, Editor-in-Chief of Blood Cancers Today, discusses Multiple Myeloma Awareness Month.
Dr. Raje reflects on the mentors who shaped her career, the evolution of myeloma treatment, and more.
The four-year OS rate from the first randomization was 94% in patients without high-risk cytogenetic abnormalites.
The OPTIMUM/MUKnine clinical trial aimed to reduce the risk of relapse before and after AHSCT in ultrahigh-risk MM.
The new FDA decision follows its granting of Breakthrough Therapy Designation to elranatamab in November 2022.
Advocates hope it will bring much-needed changes to patient care for complex cancers—including hematologic malignancies.
The investigators plan to continue using the monitoring strategies and further study patient outcomes.
The research shows an emerging target for the development of novel CAR T-cell immunotherapies.
Idecabtagene vicleucel led to “deeper and more durable responses” than standard regimens in the KarMMa-3 trial.
Thomas G. Martin, MD, and Saad Z. Usmani, MD, MBA, FACP, debate CAR-T vs bispecific antibodies for R/R MM.
A triplet may improve PFS over lenalidomide alone in patients with multiple myeloma who underwent induction and AHSCT.
A new method to detect MRD in peripheral blood had an “unprecedented sensitivity” level in multiple myeloma.
Adding isatuximab to carfilzomib and dexamethasone improved PFS in multiple myeloma, regardless of relapse time.
BMS-986393, a GPRC5D-directed CAR-T, had a "favorable” safety profile with “promising” preliminary efficacy in R/R MM.
The FDA received a Biologics License Application for the use of talquetamab in patients with R/R multiple myeloma.
Elranatamab was granted Breakthrough Therapy Designation by the U.S. FDA for relapsed/refractory multiple myeloma.
The U.S. FDA has accepted for review and filed the New Drug Application for motixafortide.
Adding vorinostat to lenalidomide maintenance therapy did not improve survival over lenalidomide in multiple myeloma.
Shambavi Richard, discusses a retrospective study on extramedullary disease and CAR-T in multiple myeloma.
Ajai Chari, MD, of Mount Sinai School of Medicine, discusses results from the MonumenTAL-1 phase I/II study of talquetamab.
Patients with multiple myeloma receiving BCMA-targeted therapies are at high risk of infectious complications.
Gary Schiller, MD, of the University of California, Los Angeles, discusses the STOMP study.
Robert Orlowski, MD, PhD, discusses bispecific antibodies and novel targets in myeloma with Chadi Nabhan, MD, MBA, FACP.
Blood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, discusses novel therapies in myeloma, MRD data, and more.
Thomas Martin, MD, discusses advances in frontline treatments for multiple myeloma, the need for novel agents, and more.
Patients with heavily pretreated multiple myeloma who received bispecific CAR T-cells had an OS rate of 83.9%.
Sandy Wong, MD, discusses results from a phase I first-in-human study of alnuctamab in patients with relapsed/refractory MM.
The phase I UNIVERSAL trial showed allogeneic CAR-T therapy led to “significant and durable responses” in patients with ...
Use of drugs with alternative modes of action may be needed to overcome persistent MRD positivity in myeloma.
Selinexor combinations had moderate efficacy in real-world patients with relapsed or refractory multiple myeloma.
A new study presented at the 2022 ASH Annual Meeting identified causes of the increased myeloma risk in Black Americans.
BCMA-directed CAR-T led to a CR in 75% in relapsed/refractory multiple myeloma who received allogeneic HSCT.
A new study suggests many interventional phase III clinical trials in myeloma didn't clearly define high-risk disease.
More genetic information is needed to investigate the link between racial ancestry and outcomes in multiple myeloma.
Selinexor plus rituximab, gemcitabine, cisplatin and dexamethasone had encouraging activity in patients with B-cell lymphoma.
Iberdomide plus dexamethasone showed encouraging efficacy and safety in triple-class-exposed R/R myeloma anti-BCMA therapy.
A GPRC5D-targeted autologous chimeric antigen receptor (CAR) T-cell therapy had “promising” preliminary efficacy.
At Blood Cancers Today, we have compiled the year's top content awards as doled out by the Twitterverse.
AgenT-797 is a scalable, off-the-shelf therapy that retains potent cytotoxicity after cryopreservation.
Findings support daratumumab plus lenalidomide and dexamethasone treatment for at least 18 months in MM...
Ciltacabtagene autoleucel led to responses in 61.5% of patients with multiple myeloma...
The phase III DREAMM-3 trial did not meet its primary endpoint...
A GPRC5D-targeted CAR T-cell therapy led to a 71% response rate in patients with heavily pretreated multiple myeloma...
The FDA has granted accelerated approval for the use of teclistamab in adults with relapsed or refractory multiple myeloma.
Health-related quality of life improved in patients with R/R MM following treatment with the CAR T-cell treatment...
A single infusion of ciltacabtagene autoleucel led to impressive overall response rates...
A new study suggests the current reference intervals for serum free light chain concentrations...
Talquetamab demonstrated “highly promising efficacy” in heavily pretreated patients with...
The phase I/II MajesTEC-1 study demonstrated that teclistamab produced a high rate of deep...
We are entering the great era of immunotherapy in multiple myeloma, as we’ve had significant...
The European Commission (EC) has granted marketing authorization for melphalan flufenamide...
The European Commission granted Conditional Marketing Authorization for teclistamab as a...
The committee overwhelmingly voted that melphalan flufenamide has not demonstrated benefit...
Blood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, provides an update...
Antibiotic prophylaxis should be considered an option for patients with newly diagnosed multiple myeloma...
This triplet combination is safe and effective in patients with relapsed/refractory multiple myeloma...
CART-ddBCMA demonstrated a 100% overall response rate in patients with relapsed/refractory multiple myeloma.
Patients with both multiple myeloma (MM) and secondary immunodeficiencies (SID) face...
Ciltacabtagene autoleucel led to an overall response rate of nearly 98% in heavily pretreated...
A triplet treatment plus autologous stem-cell transplantation was associated with longer progression...
Treatment with teclistamab, a T-cell–redirecting bispecific antibody, led to a “high rate of deep and durable...
Doris Hansen, MD, of the Moffitt Cancer Center, spoke about the research during an oral abstract presentation at IMS.
Adding a monoclonal antibody to a triplet treatment significantly lowered the risk of disease...
A single infusion of ciltacabtagene autoleucel “resulted in deep and durable responses” in...
The data were from the phase III DETERMINATION trial...
Carfilzomib, lenalidomide, and dexamethasone improved progression-free survival (PFS) over...
Adding ixazomib to pomalidomide and dexamethasone improved progression-free survival rates...
The report showed significant demographic and geographic imbalances in pivotal clinical trials leading to drug approval.
The European Commission (EC) has granted marketing authorization for selinexor, an oral exportin 1 inhibitor...
The EMA’s CHMP recommendation is based on positive results from the multicohort, open-label...
The benefit of maintenance therapy with ixazomib after allogenic hematopoietic stem cell transplantation...
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use issued...
The genetic signature consists of the genes WNT10A, DUSP1, and ETV7...
QXL138AM is a masked immunocytokine comprised of a CD138-targeted antibody fused with...
The use of the CD38-directed monoclonal antibody daratumumab was associated with ocular events...
The FDA has cleared the IND application for LAVA-051, humanized Gammabody designed to activate...
LAVA-051 consists of two single domain antibodies linked via a short five amino acid glycine-serine linker.
The ORR was 96%, including 92% at the level of VGPR, and the MRD negativity rate was 62%...
Among 37 evaluable patients, the ORR was 78%, and 27 patients had a VGPR or better...
In myeloma, isatuximab plus carfilzomib and dexamethasone (Isa-Kd) resulted in clinically improved...
IgD myeloma constitutes about 1% of myelomas and has worse prognosis than other subtypes...
Belantamab mafodotin is a BCMA targeted antibody drug conjugate approved for adult patients...
The study explored adding daratumumab to RVd and VTd regimens for patients with multiple myeloma...
The median PFS with the three-drug combination was higher compared with carfilzomib and dexamethasone alone.
Authors provide a case that demonstrates the real-world challenges of managing older, frail adults with newly diagnosed MM.
Drs. Voorhees and Martin debate frontline treatment for fit patients with multiple myeloma.
A small study observed a link between BMI and progression of monoclonal gammopathy of undetermined significance.
However, the three-drug combination improved survival in the relapsed/refractory setting.
Adding ixazomib to this treatment regimen did not improve survival outcomes, according to results of the MUKeight trial
A study has identified a very high prevalence of all monoclonal gammopathies in high-risk individuals aged 50 years or older.
A study identified differences in molecular features that may drive clinical disparities seen in patients with myeloma.
Few patients with myeloma benefit from CAR-T cell therapy, according to a Viewpoint.
Findings support the use of MRD negativity as a prognostic tool to measure deep response, leading to improved PFS.
A phase I study is underway to assess ALLO-605.
Minimal residual disease (MRD) negativity after autologous hematopoietic cell transplantation (AHCT) was associated with ...
Study finds that a third dose of the COVID-19 vaccine increased antibodies in multiple myeloma patients, regardless of prior ...
Immune checkpoint inhibitors can lower the risk of developing neurologic adverse events (NAEs) more than other cancer ...
New legislation would set time limits around FDA accelerated approvals.
According to a recent HHS report, the percentage of uninsured Black Americans has decreased since the ACA became law in 2010.
Cilta-cel has been approved by the FDA for the treatment of patients with relapsed or refractory multiple myeloma who have ...
Clinicians are excited to see how many patients could benefit with CAR T-cell therapy.
Teclistamab produced meaningful and durable responses in patients with heavily pretreated relapsed or refractory multiple ...
Pivotal trials that supported FDA approval of CAR T-cell therapies had low proportions of Black patients enrolled.
Researchers explored whether population-based screening for MGUS could increase the frequency of patients with multiple ...
Post-transplant response-adapted consolidation therapy with Dara-KRd using MRD led to high rates of MRD negativity in ...
Welcome to the second issue of Blood Cancers Today, where we’re continuing to share stories and updates on data that ...
Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute, shares his thoughts.
Dr. Laubach, from Dana-Farber Cancer Institute, reviews follow-up data from the phase II GRIFFIN trial.
Patients with hematologic malignancies have a significantly higher rate of composite thrombotic outcomes.
Researchers have discovered that chemotherapy and COVID-19 infection cause neuro-inflammation in similar ways.
Editor-in-Chief Sagar Lonial, MD, FACP, introduces the new publication from SOHO.
At SOHO 2021, Susan O'Brien, MD, and Hagop Kantarjian, MD, addressed trends in hematologic malignancies.
Daratumumab and hyaluronidase-fihj, in combination with carfilzomib and dexamethasone (Kd), has received U.S. Food and Drug ...
The pace of change in blood cancers is quite dramatic, and new paradigms of treatment, assessment, and pathogenesis occur ...
Noopur Raje, MD, says the future of BCMA-directed CAR T-cell therapies may lie with next-generation agents such as bb21217.
Noopur Raje, MD, discusses the safety and efficacy results of the CRB-402 trial.
In a study, researchers sought to calculate healthcare costs associated with triple class exposure (TCE) to multiple myeloma ...
Patients in the trial were treated for lymphoma, leukemia, or multiple myeloma.
Older patients are at a significantly increased risk of immune-related AEs.
A study published in Internal Medicine evaluated the safety profile of ixazomib in a cohort of Japanese patients with ...
Researchers sought to discern the effect of COVID-19 countermeasures on treatment outcomes in a patient population receiving ...
Several factors are correlated with palliative care use among patients with various cancers, but literature is lacking on ...
The LocoMMotion study provides real-world data on outcomes in triple-class exposed MM patients receiving standard of care.
Vikas A. Gupta, MD, PhD and Lawrence H. Boise, PhD ...
Faith Davies, MBBCh, MD MRCP, MRCPath ...
A study published in Environment International reported an elevated risk of multiple myeloma (MM) among female agricultural ...
In a phase II prospective clinical trial, researchers evaluated the effectiveness of a personalized sequential therapy for ...
A study evaluated factors associated with intense end-of-life care among patients younger than 40 with blood cancer.
Researchers of a study investigated the relationship between chronic kidney disease and multiple myeloma (MM) in a South ...
Black patients with multiple myeloma (MM) who receive upfront hematopoietic autologous cell transplantation (ASCT) have ...
Racial and ethnic minorities experience well-documented disparities across the cancer trajectory.
The research team intends to evaluate the biological mechanisms behind blood clotting in patients with cancer.
Socioeconomic status (SES) and race/ethnicity should be considered when planning multiple myeloma (MM) interventions, ...
Socioeconomic factors play a big role in multiple myeloma (MM) disparities, according to a study published in ...
A study published in Blood Advances found that a gene linked to multiple myeloma (MM) prognosis is expressed less frequently ...
A study published in JCO Global Oncology evaluated mid-to long-term outcomes of multiple myeloma (MM) treatment in Peru. ...
A study of patients with multiple myeloma (MM) in Latin America found that major bone complications are linked to increased ...
A study published in Bone Marrow Transplantation evaluated whether patient characteristics impacted the timeline to return to ...
Experts focus on the latest news and clinical development and impact for multiple myeloma.
Experts discuss treatment options related to anti-CD38 based combination triplets.
Ola Landgren, MD, PhD, Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami ...
Elisa S. Weiss, PhD, Senior Vice President, Education, Services & Health Research, LLS, New York ...
Redefining Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma ...
Zainab Shahid, MD, FACP, and Shaji K. Kumar, MD ...
Urvi A. Shah, MD, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York ...
María-Victoria Mateos, MD, PhD, Borja Puertas MD, and Veronica González-Calle MD, PhD ...
The use of hematopoietic stem cell transplantation (AHCT) is associated with excellent 2-year outcomes in multiple myeloma ...
A cross-sectional survey study involved patients treated in Mexico City for lymphoma, leukemia, or multiple myeloma.
Drs. Saad Usumani and Sydney Lu discuss adjusting multiple myeloma treatments to the realities of the COVID-19 pandemic.
A study found no discernible difference in the usage rate of hematopoietic cell transplantation (HCT) between Black and White ...
A recent study shows that multiple sites of extramedullary-bone related (EMB) lesions are poor prognostic factors for newly ...
A study found sex differences in high-risk cytogenetics among patients with multiple myeloma (MM), though these differences ...
Clarithromycin plus lenalidomide and dexamethasone for the treatment of multiple myeloma (MM) did not offer a survival ...
Patient race and ethnicity were bound to be associated with hematopoietic stem/progenitor cells (HSPC) mobilization, ...
An analysis of Asian patients with multiple myeloma found that treatment with subcutaneous daratumumab (DARA SC) was ...
A study indicates that BCL2 dependence, as well as CD38 expression, are significantly linked with the differentiation ...
Elevated membrane expression of junctional adhesion molecule A (JAM-A) on multiple myeloma endothelial cells (MMECs) ...
Communication between the clinician and patient, as a two-way conversation, clarity on goals for treatment and treatment ...
Janssen and Legend Biotech announced new data for BCMA-directed CAR-T cell therapy cilta-cel for relapsed/refactory MM.
Researchers for a recent study evaluated the prevalence and characteristics of second primary malignancies (SPMs) in Black ...
A study did not observe racial disparities in the use of autologous hematopoietic cell transplantation (HCT) consolidative ...
Insurance status was associated with survival among patients with multiple myeloma (MM), according to new study results ...
A new study reports on county-level socioeconomic disparities in the distribution of multiple myeloma (MM) clinical trial ...
A study found that a high expression of the coding gene human leukocyte antigen-E (HLA-E) is associated with advanced disease ...
Although physical activity and exercise programs have shown benefit for patients with multiple myeloma (MM), clinical ...
In patients with multiple myeloma (MM), higher patient-rated pain severity was found to be significantly associated with ...
Treatment with a regimen of bortezomib, melphalan, and prednisone (VMP) with or without daratumumab (D-VMP) led to similar ...
Incidence of multiple myeloma (MM) has more than doubled globally since 1990, according to an analysis published in BMC ...
Real-world data showed that upfront autologous hematopoietic stem cell transplantation (AHCT) for treatment of multiple ...
A predictive tool may help primary care physicians identify patients at high-risk of multiple myeloma (MM), according to a ...
Researchers from The Mount Sinai Health System in New York City evaluated racial disparities in time to autologous ...
A study published in the Annals of Hematology used real-world evidence to conduct head-to-head comparisons of triplet ...
A study published in Clinical Lymphoma, Myeloma, & Leukemia evaluated the efficacy of intravenous immunoglobin (IVIG) to ...
Nikhil Munshi, MD, had a conversation with Orsi Giricz, PhD, from LLS, to discuss the recent approval of Abecma and his role ...
Peter Voorhees, PhD ...
Neha Korde, MD ...
Based on the LLS Professional Education Webcast: Multiple Myeloma: Diagnosis, Treatment, and Side Effects Management ...
A study from researchers at Sungkyunkwan University in Seoul, South Korea assessed how depression impacts ...
A study published in The Lancet Haematology reviewed responses to the first dose of the SARS-CoV-2 vaccine in patients with ...
Douglas Sborov, MD, MS, discusses the impact of the COVID-19 pandemic on treatment and care for patients with MM.
Douglas Sborov, MD, speaks about recent initiatives to expand eligibility to multiple myeloma clinical trials.
On March 10, 2021, the National Comprehensive Cancer Network Vaccination Advisory Committee released their recommendations ...
On March 31, 2021, the FDA extended the indication of isatuximab for use in combination with carfilzomib and dexamethasone ...
The U.S. Food and Drug Administration (FDA) approved idecabtagene vicleucel (ide-cel) for the treatment of adults with ...
A study published in the European Journal of Haematology calculated costs and survival outcomes associated with ...
Two studies that assessed multiple myeloma care in Latin America found significant differences in access and outcomes ...
A study published in Clinical Lymphoma, Myeloma & Leukemia evaluated the burden of outpatient autologous hematopoietic ...
A study published in BMC Medicine evaluated physical and mental health-related outcomes in patients with multiple myeloma ...
Parameswaran Hari, MD, weighs in on clinical considerations for selecting CAR T cell therapy for multiple myeloma.
A study published in the Journal of Medical Economics calculated costs associated with the use of different proteasome ...
Parameswaran Hari, MD, speaks about myeloma research presented at the virtual 2020 ASH Annual Meeting.
On March 1, 2021, the U.S. Food and Drug Administration granted accelerated approval to melphalan flufenamide (melflufen) in ...
The latest updates from the KarMMA trial, published in The New England Journal of Medicine, showed that treatment with ...
Findings presented at the ASH 2020 Annual Meeting & Exposition found that almost half of patients with multiple myeloma (MM) ...
A study published online in the Journal of Oncology Pharmacy Practice calculated economic outcomes of patients with ...
An early access treatment protocol (EAP) found that daratumumab monotherapy was safe in a population of patients with heavily ...
In a collaborative effort, researchers from the Dana-Farber Cancer Institute, the U.S. Food and Drug Administration, and the ...
Patients with multiple myeloma who underwent double autologous hematopoietic cell transplantation did not have better overall ...
A study published in the British Journal of Cancer assessed whether esterase gene expression is of clinical significance in ...
Raj Chakraborty, MD, discusses how new research on treatments for multiple myeloma may impact the treatment landscape.
Raj Chakraborty, MD, speaks about considerations for selecting between BiTEs and CAR T-cell therapy.
Raj Chakraborty, MD, speaks about the benefits of antibody drug conjugates (ADC) for multiple myeloma.
Raj Chakraborty, MD, speaks about promising results from current clinical trials for newly diagnosed multiple myeloma.
Therapeutic regimens for multiple myeloma that use a combination of the anti-CD38 monoclonal antibody daratumumab induce ...
A study from researchers at the University of Pittsburgh and other institutions aimed to evaluate the pain experiences among ...
In an analysis of real-world data, the all-oral triplet regimen of ixazomib, lenalidomide, and dexamethasone (IRD) for ...
Real-world data from a single institution showed concerningly low levels of long-term adherence to lenalidomide therapy for ...
An analysis of patients with multiple myeloma (MM) who underwent autologous hematopoietic cell transplant (AHCT) showed that ...
A new study showed evidence of racial disparities in the use of intravenous (IV) bisphosphonates among older patients ...
First-line daratumumab therapy for patients with transplant-ineligible multiple myeloma (MM) may not be cost-effective at the ...
A research team in Norway found that previous hematological malignancies were associated with a subsequent diagnosis.
ABO blood groups may play a role in the development and outcomes of multiple myeloma, according to new data published in ...
A study of farmers found that exposure to certain pesticides was associated the development with monoclonal gammopathy of ...
A study published in the British Journal of Haematology assessed updated survival data from a phase II trial of melphalan ...
According to new data published in Blood, patients with multiple myeloma (MM) who are hospitalized for COVID-19 infection ...
A study published in BMC Cancer analyzed the relationship between education level and survival in multiple myeloma and ...
A study presented at the ASH Annual Meeting found that among 6 landmark multiple myeloma clinical trials, the ineligibility ...
Iberdomide, an oral potent novel cereblon E3 ligase modulator (CELMoD), demonstrated an acceptable toxicity profile and ...
Data presented at the 2020 ASH Annual Meeting showed that the addition of subcutaneous daratumumab to pomalidomide and ...
The novel chimeric antigen receptor (CAR) T cell therapy, CT053, achieved a 100% overall response rate (ORR) for the ...
Results from the PRIME study found that P-BCMA-101, an autologous CAR T-cell therapy, was effective and safe for patients ...
Patients with high-risk myeloma may not be appropriately recognized as having high-risk disease at diagnosis, according to a ...
Insurance status was found to be significantly associated with survival for patients with multiple myeloma, according to ...
According to data presented at the 2020 ASH Annual Meeting, the use of direct oral anticoagulants effectively prevented ...
The addition of daratumumab to standard therapy improved responses in Black transplant-eligible patients with newly diagnosed ...
Venetoclax plus bortezomib and dexamethasone significantly improved survival compared with bortezomib and dexamethasone alone ...
Shaji Kumar, MD, discusses B-cell maturation antigen as a target for myeloma and belantamab mafodotin.
Sarah Holstein, MD, PhD, discusses the lack of Black patients with multiple myeloma enrolled in clinical trials.
The ENDURANCE trial assessed carfilzomib versus bortezomib plus lenalidomide and dexamethasone for newly diagnosed MM.
A study published in Blood identified the following factors as predictive of worse outcomes for patients with multiple ...
Shaji Kumar, MD, highlighted how the treatment paradigm may change in the coming years.
Bortezomib-containing treatment regimens for myeloma are associated with an increased risk for tumor lysis syndrome (TLS) in ...
A study published in BMC Cancer analyzed the relationship between education level and survival in multiple myeloma and ...
A study published in the Journal of Clinical Oncology assessed doublet versus triplet bortezomib-based therapy in patients ...
The phase III BOSTON study found that once-weekly selinexor, bortezomib, and dexamethasone is a novel, effective, and ...
Immune system cells and signal carriers amid the tumor cells undergo dramatic shifts, with alterations in both the number and ...
A study published in JAMA Oncology found that the addition of daratumumab to backbone multiple myeloma regimens improved ...
Ankit Kansagra, MD, discusses chimeric antigen receptor T-cell agents in the pipeline for multiple myeloma.
A study published in the Journal of Hematology & Oncology found that drug exposure and disease status do not impact mortality ...
A study published in Cancer Science observed that isatuximab monotherapy was an effective and well-tolerated treatment for ...
A study using whole-genome sequencing data found that patients with multiple myeloma (MM) with low genomic scar score (GSS) ...
Patients with multiple myeloma receiving statins had reduced mortality, according to a study published in Clinical Lymphoma, ...
Maintenance therapy increases survival in patients with multiple myeloma (MM) compared with observation, according to a study ...
The addition of elotuzumab to lenalidomide and dexamethasone significantly improved survival outcomes in patients with ...
A study presented at the 2020 Society of Hematologic Oncology Annual Meeting found that the addition of ixazomib to ...
Nina Shah, MD, discusses novel immunotherapy agents in development for multiple myeloma and what to know about them.
Nina Shah, MD, talks about two multiple myeloma agents granted priority review by the FDA and data on these therapeutics.
A study published in the Journal of Clinical Oncology found that ixazomib maintenance therapy extended survival in patients ...
A study published in Clinical Lymphoma, Myeloma & Leukemia evaluated the safety and efficacy of VD-PACE in combination with ...
Nina Shah, MD, discusses immunotherapy agents in the pipeline for multiple myeloma.
Patients with Hematologic Cancers Have More Severe Reaction to COVID-19 Than Those With Solid Tumors
The study included a cohort of 1044 adults with cancer who were enrolled in the UK Coronavirus Cancer Monitoring Project.
A study published in the Journal of Geriatric Oncology found that rates of no treatment and early mortality are higher in ...
A study published in Clinical Cancer Research confirmed that lenalidomide 10 mg to 15 mg per day is an effective dose to ...
Sarah Holstein, MD, PhD, discusses the myeloma treatment pipeline and how these agents may change the treatment landscape.
Researchers compared the efficacy of lenalidomide and dexamethasone paired with carfilzomib or bortezomib for the treatment ...
Dr. Usmani discusses an indirect treatment comparison study which assesses daratumumab plus lenalidomide and dexamethasone.
In a head-to-head comparison of minimal residual disease (MRD) versus stringent complete response (sCR) to determine clinical ...
Sarah Holstein, MD, PhD, talks about BCMA as a target of interest for multiple myeloma, as well as other emerging targets.
Advertisement
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Advertisement
